Navigation Links
HIV positive and HIV negative patients have similar survival rates following liver transplant
Date:4/24/2009

Copenhagen, Denmark, Friday 24 April: HIV positive and HIV negative patients have comparable survival rates following liver transplant, according to new research presented today at EASL 2009, the Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark.

The study results showed no difference in survival rates at 1 and 5 years between HIV negative and HIV positive patients (86.5% and 74% versus 87.1% and 78%, p=0.843), suggesting a good prognosis for HIV positive patients following liver transplant. However, the study confirmed that co-infection with hepatitis C virus (HCV) is a significant predictor of poorer survival rates in patients with HIV. Survival rates at 1 and 5 years were 73% and 53% in HIV positive patients with hepatitis C versus 87% and 69% (p=0.047) in HIV negative patients with hepatitis C.

Doctor Kosh Agarwal, of the Institute of Liver Studies, Kings College Hospital, London, who led the study said: "Data on long term outcomes from liver transplantation in HIV patients is limited. These study results are valuable confirmation that selected HIV positive patients are as suitable candidates for liver transplant as HIV negative patients and should have similar access to treatment. However, those patients with co-infection with hepatitis C did less well, emphasising the need for appropriate antiviral therapy early in the course of their HCV related liver disease. In the context of co-infection, these data emphasise the need to develop newer and more innovative treatment strategies. These should include exposure to new small molecule therapies for HCV that are currently being explored in mono-infection."

The researchers conducted a prospective analysis of the UK Transplant Database to determine the long-term outcomes in HIV patients undergoing liver transplant in the UK. They examined 6,315 adult patients (>18 years) undergoing their first liver transplant between March 1994 and April 2008. The patient groups compared in this analysis included:

  1. HIV positive patients who tested negative for both hepatitis C and hepatitis B
  2. HIV negative patients with hepatitis C
  3. HIV positive patients with hepatitis C

The three patient groups were comparable according to the Model End Stage Liver Disease (MELD) scores, which is a numerical scale to score disease severity and improve organ allocation in transplantation. HIV positive patients were younger compared to HIV negative patients (mean 42.2 years versus 51.2, p=0.001) and HIV positive patients co-infected with hepatitis C were younger (mean 39.9 years versus 51.8; p=0.0001) than HIV negative patients with hepatitis C.


'/>"/>

Contact: Camilla Dormer
easlpressoffice@cohnwolfe.com
44-078-761-90439
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. The ALS Association's 'ALS Across America' Focuses On Staying Positive and Involved
2. Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
3. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
4. Economy Got You Down? Use The Principles Of Positive Psychology
5. Standard and Poors Raises Boston Scientifics Rating Outlook to Positive
6. Recent Industry Developments Reaffirm Positive Glucose Industry Outlook
7. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
8. Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
9. Prescription Copay Assistance for Patients taking Gleevec or Tasigna for Philadelphia chromosome-positive Chronic Myelogenous Leukemia (Ph+ CML)
10. Positive behavior support training curriculum
11. CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Providing broad access to ... opposition, but there is a better way to address this problem. , That was ... Pharmacy, Public Policy and Economics at the University of Southern California, who served as ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Brady ... that its B-595 and B-7569 vinyl label materials received certification ... warning labels are tested to remain intact and legible, for use on chemical drums ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... been named Agency of Record (AOR) for Theravent, Inc. , the makers ... Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand distribution in ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... products, announced an exciting new partnership with the highly regarded and well renowned ... Management’s highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize ...
(Date:4/21/2017)... Salt Lake City, UT (PRWEB) , ... April 21, 2017 , ... ... medical staffing solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has ... the way for the next chapter of growth for our agency and our ability ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  SARES•REGIS Group leased the first of ... Conejo Spectrum Business Park in Thousand ... Inc. , a biopharmaceutical company developing meaningful therapies ... have been underserved by scientific innovation, with an ... autoimmune and infectious disease. Before commencement ...
(Date:4/18/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 6.35% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/18/2017)... Research and Markets has announced the addition of the ... Radiopharmaceuticals Market, Forecast to 2023" report to their offering. ... This report assesses ... growth in the number of unit shipments over the next ... design and manufacture molecular imaging equipment. Market ...
Breaking Medicine Technology: